Basit öğe kaydını göster

dc.contributor.authorÖven Ustaalioğlu, Bala Başak
dc.contributor.authorBilici, Ahmet
dc.contributor.authorErkol Yılmaz, Burçak
dc.contributor.authorAliustaoğlu, Mehmet
dc.contributor.authorŞeker, Mesut
dc.contributor.authorVardar, Fügen
dc.contributor.authorGümüş, Mahmut
dc.date.accessioned10.07.201910:49:13
dc.date.accessioned2019-07-10T19:36:32Z
dc.date.available10.07.201910:49:14
dc.date.available2019-07-10T19:36:32Z
dc.date.issued2014en_US
dc.identifier.citationÖven Ustaalioğlu, B. B., Bilici, A., Erkol Yılmaz, B., Aliustaoğlu, M., Şeker, M., Vardar, F. ... Gümüş, M. (2014). Important factors affecting adjuvant treatment decision in stage IA breast cancer patients in Turkey. Breast Care, 9(2), 123-127. https://dx.doi.org/10.1159/000360929en_US
dc.identifier.issn1661-3791
dc.identifier.urihttps://hdl.handle.net/20.500.12511/1192
dc.identifier.urihttps://dx.doi.org/10.1159/000360929
dc.description.abstractIntroduction: In Turkey, the gene expression profile test is not standard, so adjuvant treatment is planned according to clinicopathological factors. Therefore, we retrospectively analyzed important parameters that affect the decision on adjuvant chemotherapy, and also factors related to survival in stage IA breast cancer patients in Turkey. Methods: We retrospectively evaluated 347 stage IA patients. The relationship between the clinicopathological parameters and adjuvant chemotherapy was analyzed. Results: The median age and follow-up time were 52 years (range: 25-86) and 22.6 months (range: 1-113), respectively. The 5-year disease-free survival (DFS) and overall survival (OS) rates were 87.9% and 98.7%, respectively, but the median DFS was not reached. Age, estrogen receptor (ER) status, human epidermal growth factor receptor 2 (HER2) status, and the presence of triple-negative breast tumor (TNBC) were related to DFS, and lymphovascular invasion (LVI), perineural invasion (PNI), HER2 status, the presence of TNBC, and recurrence were related to OS (p < 0.05). Furthermore, age, menopausal status, multicentricity, grade, tumor size, necrosis, ER, the presence of TNBC, and HER2 were found to be related to adjuvant therapy decision (p < 0.05). All these parameters, in addition to LVI and PNI, were independent factors for chemotherapy by logistic regression analysis. Conclusions: In decisions about adjuvant therapy in stage IA breast cancer patients, clinicopathological factors should be kept in mind.en_US
dc.language.isoengen_US
dc.publisherS. Karger AGen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectAdjuvant Therapyen_US
dc.subjectBreast Canceren_US
dc.subjectChemotherapyen_US
dc.subjectStage IAen_US
dc.titleImportant factors affecting adjuvant treatment decision in stage IA breast cancer patients in Turkeyen_US
dc.typearticleen_US
dc.relation.ispartofBreast Careen_US
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalıen_US
dc.identifier.volume9en_US
dc.identifier.issue2en_US
dc.identifier.startpage123en_US
dc.identifier.endpage127en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.identifier.doi10.1159/000360929en_US
dc.identifier.wosqualityQ2en_US
dc.identifier.scopusqualityQ3en_US


Bu öğenin dosyaları:

Thumbnail

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster